Literature DB >> 30344703

Overexpression of miR-574-3p suppresses proliferation and induces apoptosis of chronic myeloid leukemia cells via targeting IL6/JAK/STAT3 pathway.

Haoying Yang1, Jun Zhang2, Jiuping Li1, Furong Zhao1, Yao Shen2, Xuemei Xing2.   

Abstract

The present study aimed to elucidate the potential roles and regulatory mechanism of microRNA (miR)-574-3p in the development of chronic myeloid leukemia (CML). The expression of miR-574-3p in peripheral blood obtained from patients with CML was examined. Subsequently, miR-574-3p was overexpressed and suppressed in CML K562 cells to further investigate the effects of miR-574-3p on cell proliferation, and apoptosis. Furthermore, a luciferase reporter assay was performed to investigate whether interleukin-6 (IL-6) was a target of miR-574-3p. In addition, the regulatory association between miR-574-3p and the IL-6/Janus kinase (JNK)/signal transducer and activator of transcription-3 (STAT3) signaling pathway was explored. The expression of miR-574-3p in the peripheral blood obtained from patients with CML was significantly lower compared with that in healthy controls. Overexpression of miR-574-3p significantly inhibited the proliferation and induced the apoptosis of K562 cells, whereas suppression of miR-574-3p exhibited opposite effects. In addition, IL-6 was identified to be a direct target of miR-574-3p. Overexpression of IL-6 significantly promoted the proliferation and inhibited the apoptosis of K562 cells. Furthermore, overexpression of miR-574-3p inhibited the activation of the JAK/STAT3 signaling pathway, which was rescued by overexpression of IL-6. The results of the current study indicate that miR-574-3p overexpression may serve an important role in inhibiting proliferation and inducing apoptosis of K562 cells via suppression of IL-6/JAK/STAT3 signaling pathway activation. miR-574-3p may serve as a potential therapeutic target for CML.

Entities:  

Keywords:  IL6/JAK/STAT3 pathway; apoptosis; chronic myeloid leukemia; miR-574-3p; proliferation

Year:  2018        PMID: 30344703      PMCID: PMC6176133          DOI: 10.3892/etm.2018.6700

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  28 in total

1.  Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients.

Authors:  Roberto Ciarcia; Maria Teresa Vitiello; Massimiliano Galdiero; Carmen Pacilio; Valentina Iovane; Danila d'Angelo; David Pagnini; Giuseppe Caparrotti; Daniele Conti; Valentina Tomei; Salvatore Florio; Antonio Giordano
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

2.  miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.

Authors:  Yan Li; Lifen Zhao; Nana Li; Yuan Miao; Huimin Zhou; Li Jia
Journal:  Oncol Rep       Date:  2017-02-17       Impact factor: 3.906

Review 3.  Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

Authors:  T L Holyoake; X Jiang; M W Drummond; A C Eaves; C J Eaves
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

4.  Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.

Authors:  Yue Liu; Yanbin Song; Wenli Ma; Wenling Zheng; Hong Yin
Journal:  Leuk Res       Date:  2013-01-01       Impact factor: 3.156

Review 5.  Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.

Authors:  Elias Jabbour; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2014-05       Impact factor: 10.047

6.  MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin.

Authors:  Burçin Tezcanlı Kaymaz; Vildan Bozok Cetintaş; Cağdaş Aktan; Buket Kosova
Journal:  Tumour Biol       Date:  2014-05-30

Review 7.  MiRNA s in oesophageal squamous cancer.

Authors:  Y Chu; H Zhu; L Lv; Y Zhou; J Huo
Journal:  Neth J Med       Date:  2013-03       Impact factor: 1.422

8.  MicroRNA (miRNA) in cancer.

Authors:  Kaladhar B Reddy
Journal:  Cancer Cell Int       Date:  2015-04-02       Impact factor: 5.722

9.  MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.

Authors:  Zhu Xishan; Lin Ziying; Du Jing; Liu Gang
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

10.  The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma.

Authors:  Tomoyuki Okumura; Hirohumi Kojima; Takeshi Miwa; Shinichi Sekine; Isaya Hashimoto; Shozo Hojo; Takuya Nagata; Yutaka Shimada
Journal:  World J Surg Oncol       Date:  2016-08-26       Impact factor: 2.754

View more
  7 in total

Review 1.  MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers.

Authors:  Mehdi Sajjadi-Dokht; Talar Ahmad Merza Mohamad; Heshu Sulaiman Rahman; Marwah Suliman Maashi; Svetlana Danshina; Navid Shomali; Saeed Solali; Faroogh Marofi; Elham Zeinalzadeh; Morteza Akbari; Ali Adili; Ramin Aslaminabad; Majid Farshdousti Hagh; Mostafa Jarahian
Journal:  Genes Dis       Date:  2021-12-03

2.  Three-dimensional DNA tweezers serve as modular DNA intelligent machines for detection and regulation of intracellular microRNA.

Authors:  Lin Zhou; Mingxuan Gao; Weiling Fu; Yunxia Wang; Dan Luo; Kai Chang; Ming Chen
Journal:  Sci Adv       Date:  2020-05-29       Impact factor: 14.136

3.  MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer.

Authors:  Wen-Cui Li; Yan-Qiong Wu; Bo Gao; Chao-Yun Wang; Juan-Juan Zhang
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

Review 4.  MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools.

Authors:  Ioannis Kyriakidis; Konstantinos Kyriakidis; Aspasia Tsezou
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

5.  Pan-cancer analysis of forkhead box Q1 as a potential prognostic and immunological biomarker.

Authors:  Qiguan Dong; Lirong Yan; Qingbang Xu; Xianliang Hu; Yan Yang; Ruiwu Zhu; Qian Xu; Yuchao Yang; Bengang Wang
Journal:  Front Genet       Date:  2022-09-01       Impact factor: 4.772

6.  An Anti-inflammatory microRNA Signature Distinguishes Group 3 Innate Lymphoid Cells From Natural Killer Cells in Human Decidua.

Authors:  Andrea Pelosi; Claudia Alicata; Nicola Tumino; Tiziano Ingegnere; Fabrizio Loiacono; Maria Cristina Mingari; Lorenzo Moretta; Paola Vacca
Journal:  Front Immunol       Date:  2020-02-06       Impact factor: 7.561

7.  Novel Markers in Pediatric Acute Lymphoid Leukemia: The Role of ADAM6 in B Cell Leukemia.

Authors:  Laila Alsuwaidi; Mahmood Hachim; Abiola Senok
Journal:  Front Cell Dev Biol       Date:  2021-06-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.